Activation of fibroblast growth factor receptor 3 and oncogene-induced senescence in skin tumours

British Journal of Dermatology

Volumn 160, Issue 6, 2009, Pages 1258-1263

  Hida, Y ^a   Kubo, Y ^a   Arase, S ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

FGFR3; Gene mutation; Oncogene induced senescence; Protein Expression; Skin tumours

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; HISTONE H2AX;

ACTINIC KERATOSIS; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEBORRHEIC KERATOSIS; SENESCENCE; SKIN CARCINOGENESIS; SKIN SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL CARCINOMA;

BOWEN'S DISEASE; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; HUMANS; KERATOSIS, ACTINIC; KERATOSIS, SEBORRHEIC; ONCOGENES; POINT MUTATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SKIN AGING; SKIN NEOPLASMS; TRANSCRIPTIONAL ACTIVATION;

EID: 66149123020     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09068.x     Document Type: Article

References (29)

1. E600- associated senescence-like cell cycle arrest of human naevi. Nature 2005 436 : 720 4.
2. Venkitaraman AR. Aborting the birth of cancer. Nature 2005 434 : 829 30.
3. Bartkova J, Hořejši Z, Koed K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005 434 : 864 70.
4. Collado M, Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 2006 6 : 472 6.
5. Di Micco R, Fumagalli M, Cicalese A et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006 444 : 638 42.
6. Bartkova J, Rezaei N, Liontos M et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006 444 : 633 7.
7. L'Hôte CG, Knowles MA. Cell responses to FGFR3 signaling: growth, differentiation and apoptosis. Exp Cell Res 2005 304 : 417 31.
8. Cappellen D, de Oliveira C, Ricol D et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999 23 : 18 20.
9. Billerey C, Chopin D, Aubriot-Lorton M-H et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001 158 : 1955 9.
10. Kimura T, Suzuki H, Ohashi T et al. The incidence of thanatophoric dysplasia mutations in FGFR3 genes is higher in low-grade or superficial bladder carcinomas. Cancer 2001 92 : 2555 61.
11. van Rhijn BW, van der Kwast TH, Vis AN et al. FGFR3 and p53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004 64 : 1911 14.
12. Chesi M, Nardini E, Brents LA et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997 16 : 260 4.
13. Zhang Y, Hiraishi Y, Wang H et al. Constitutive activating mutation of the FGFR3b in oral squamous cell carcinoma. Int J Cancer 2005 117 : 166 8.
14. Jang J-H, Shin K-H, Park J-G. Mutation in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001 61 : 3541 3.
15. Bernard-Pierrot I, Brams A, Dunois-Lardé C et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2006 27 : 740 7.
16. Logié A, Dunois-Lardé C, Rosty C et al. Activating mutations of tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 2005 14 : 1153 60.
17. Hafner C, van Oers JMM, Hartmann A et al. High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol 2006 126 : 2404 7.
18. Hafner C, Vogt T, Hartmann A et al. FGFR3 mutations in benign skin tumors. Cell Cycle 2006 5 : 2723 8.
19. Hafner C, Hartmann A, Real FX et al. Spectrum of FGFR3 mutations in multiple intraindividual seborrheic keratoses. J Invest Dermatol 2007 127 : 1883 5.
20. Hafner C, Hartmann A, van Oers JM et al. FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization. Mod Pathol 2007 20 : 895 903.
21. Gorgoulis VG, Vassiliou LV, Karakaidos P et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005 434 : 907 13.
22. Murao K, Kubo Y, Fukuhara K et al. Three cases of Bowen's disease on the lower abdomen associated with high-risk types 16, 33, and 59 of human papillomavirus. J Am Acad Dermatol 2005 52 : 723 4.
23. INK4a overexpression associated with human papillomavirus type 16. Br J Dermatol 2005 152 : 170 3.
24. Gómez-Román JJ, Saenz P, González JC et al. Fibroblast growth factor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res 2005 11 : 459 65.
25. Takenaka H, Yasuno H, Kishimoto S. Immunolocalization of fibroblast growth factor receptors in normal and wounded human skin. Arch Dermatol Res 2002 294 : 331 8.
26. Hafner C, van Oers JMM, Vogt T et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest 2006 116 : 2201 7.
27. Karoui M, Hofmann-Radvanyi H, Zimmermann U et al. No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene 2001 20 : 5059 61.
28. Dimri GP, Lee X, Basile G et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995 92 : 9363 7.
29. INK4a expression in actinic keratosis and Bowen's disease. Br J Dermatol 2003 149 : 1006 12.